{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:25:34Z","timestamp":1780323934258,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or malignant lymphoma (ML). Efficacy and safety, along with CD34-positive cell mobilization outcomes were assessed in patients with MM, who were randomly assigned to pegfilgrastim (<jats:italic>n<\/jats:italic>\u2009=\u200930) or daily filgrastim (<jats:italic>n<\/jats:italic>\u2009=\u200931), and ML (pegfilgrastim only, <jats:italic>n<\/jats:italic>\u2009=\u200913) cohorts. In the MM cohort, CD34-positive cell counts\u2009\u2265\u20092\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg were achieved in 100% of patients in the pegfilgrastim group and 96.7% in the filgrastim group (difference: 3.3%; 80% confidence interval: \u22120.9\u20137.5%), demonstrating the non-inferiority of pegfilgrastim to filgrastim. All patients in the ML cohort achieved\u2009\u2265\u20092\u2009\u00d7\u200910<jats:sup>6<\/jats:sup>\/kg CD34-positive cell counts. The plerixafor administration rates in the MM cohort were 50.0% and 63.3% in the pegfilgrastim and filgrastim groups, respectively, and 91.7% in the ML cohort. There were no major differences in safety measures between the two groups. Although the sample size was small, particularly in the ML cohort, a single dose of pegfilgrastim demonstrated comparable efficacy and safety to daily doses of filgrastim, indicating its potential for clinical use while reducing patient burden.<\/jats:p>\n          <jats:p>Trial Registration: jRCT2011210029, NCT05007652. <\/jats:p>","DOI":"10.1038\/s41598-025-98453-7","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:52:31Z","timestamp":1745581951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Hideki","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadao","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Toyosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sonoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Shimogomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ichihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiumi","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"98453_CR1","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","volume":"20","author":"HK Duong","year":"2014","unstructured":"Duong, H. K. et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American society for blood and marrow transplantation. Biol. Blood Marrow Transpl. 20, 1262\u20131273 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"98453_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1402888","volume":"371","author":"A Palumbo","year":"2014","unstructured":"Palumbo, A. et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl. J. Med. 371, 895\u2013905 (2014).","journal-title":"N Engl. J. Med."},{"key":"98453_CR3","doi-asserted-by":"publisher","first-page":"963689720975397","DOI":"10.1177\/0963689720975397","volume":"29","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Comparison of survival between autologous and allogeneic stem cell transplantation in patients with relapsed or refractory b-cell non-Hodgkin lymphoma: a meta-analysis. Cell. Transpl. 29, 963689720975397 (2020).","journal-title":"Cell. Transpl."},{"key":"98453_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen, J. J. & Blaise, D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127, 62\u201370 (2016).","journal-title":"Blood"},{"key":"98453_CR5","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1200\/JCO.20.02724","volume":"39","author":"N Kr\u00f6ger","year":"2021","unstructured":"Kr\u00f6ger, N. et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo study). J. Clin. Oncol. 39, 3318\u20133327 (2021).","journal-title":"J. Clin. Oncol."},{"key":"98453_CR6","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1089\/scd.2004.13.598","volume":"13","author":"AP Jillella","year":"2004","unstructured":"Jillella, A. P. & Ustun, C. What is the optimum number of CD34\u2009+\u2009peripheral blood stem cells for an autologous transplant? Stem Cells Dev. 13, 598\u2013606 (2004).","journal-title":"Stem Cells Dev."},{"key":"98453_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","volume":"16","author":"P Wuchter","year":"2010","unstructured":"Wuchter, P. et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol. Blood Marrow Transpl. 16, 490\u2013499 (2010).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"98453_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3906\/sag-2001-173","volume":"50","author":"E Alada\u011f Karakulak","year":"2020","unstructured":"Alada\u011f Karakulak, E. et al. CD34\u2009+\u2009hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Turk. J. Med. Sci. 50, 1851\u20131856 (2020).","journal-title":"Turk. J. Med. Sci."},{"key":"98453_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2165\/00003495-200262080-00012","volume":"62","author":"MP Curran","year":"2002","unstructured":"Curran, M. P. & Goa, K. L. Pegfilgrastim. Drugs 62, 1207\u20131215 (2002).","journal-title":"Pegfilgrastim Drugs"},{"key":"98453_CR10","first-page":"761","volume":"111","author":"N Kr\u00f6ger","year":"2000","unstructured":"Kr\u00f6ger, N. et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br. J. Haematol. 111, 761\u2013765 (2000).","journal-title":"Br. J. Haematol."},{"key":"98453_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2174\/1381612043452613","volume":"10","author":"G Molineux","year":"2004","unstructured":"Molineux, G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta\u00ae). Curr. Pharm. Des. 10, 1235\u20131244 (2004).","journal-title":"Curr. Pharm. Des."},{"key":"98453_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang, B. B. & Kido, A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin. Pharmacokinet. 50, 295\u2013306 (2011).","journal-title":"Clin. Pharmacokinet."},{"key":"98453_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil, A. M. et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 23, 525\u2013545 (2015).","journal-title":"Support Care Cancer"},{"key":"98453_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky, J. et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann. Oncol. 27, 111\u2013118 (2016).","journal-title":"Ann. Oncol."},{"key":"98453_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00508-017-1205-z","volume":"129","author":"B Skopec","year":"2017","unstructured":"Skopec, B., Skerget, M., Zontar, D., Zadnik, V. & Zver, S. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients. Wien Klin. Wochenschr. 129, 545\u2013551 (2017).","journal-title":"Wien Klin. Wochenschr"},{"key":"98453_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/bmt.2014.112","volume":"49","author":"KE Herbert","year":"2014","unstructured":"Herbert, K. E. et al. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial. Bone Marrow Transpl. 49, 1056\u20131062 (2014).","journal-title":"Bone Marrow Transpl."},{"key":"98453_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.bbmt.2018.09.005","volume":"25","author":"NL Watts","year":"2019","unstructured":"Watts, N. L. et al. Mobilization of hematopoietic progenitor cells for autologous transplantation using pegfilgrastim and plerixafor: efficacy and cost implications. Biol. Blood Marrow Transpl. 25, 233\u2013238 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"98453_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/jca.21816","volume":"35","author":"H Goto","year":"2020","unstructured":"Goto, H. et al. Feasibility and efficacy of low-dose pegfilgrastim for CD34\u2009+\u2009cell mobilization in lymphoma. J. Clin. Apher. 35, 413\u2013419 (2020).","journal-title":"J. Clin. Apher"},{"key":"98453_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/scd.1.1996.5.213","volume":"5","author":"DR Sutherland","year":"1996","unstructured":"Sutherland, D. R., Anderson, L., Keeney, M., Nayar, R. & Chin-Yee, I. The ISHAGE guidelines for CD34\u2009+\u2009cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J. Hematother. 5, 213\u2013226 (1996).","journal-title":"J. Hematother"},{"key":"98453_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/107327481502200111","volume":"22","author":"LJ Costa","year":"2015","unstructured":"Costa, L. J. et al. Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma. Cancer Control. 22, 87\u201394 (2015).","journal-title":"Cancer Control"},{"key":"98453_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jca.21360","volume":"30","author":"SA Tuchman","year":"2015","unstructured":"Tuchman, S. A. et al. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J. Clin. Apher. 30, 176\u2013182 (2015).","journal-title":"J. Clin. Apher"},{"key":"98453_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/bmt.2015.190","volume":"50","author":"GL Uy","year":"2015","unstructured":"Uy, G. L. et al. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transpl. 50, 1513\u20131518 (2015).","journal-title":"Bone Marrow Transpl."},{"key":"98453_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/bmt.2014.39","volume":"49","author":"M Mohty","year":"2014","unstructured":"Mohty, M. et al. Autologous haematopoietic stem cell mobilization in multiple myeloma and lymphoma patients: a position statement from the European group for blood and marrow transplantation. Bone Marrow Transpl. 49, 865\u2013872 (2014).","journal-title":"Bone Marrow Transpl."},{"key":"98453_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1046\/j.1537-2995.2003.00361.x","volume":"43","author":"V Moncada","year":"2003","unstructured":"Moncada, V., Bolan, C., Yau, Y. Y. & Leitman, S. F. Analysis of PBPC cell yields during large-volume leukapheresis of patients with a poor mobilization response to filgrastim. Transfusion 43, 495\u2013501 (2003).","journal-title":"Transfusion"},{"key":"98453_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/bmt.2011.82","volume":"47","author":"A Olivieri","year":"2012","unstructured":"Olivieri, A. et al. Proposed definition of \u2018poor mobilizer\u2019 in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto Di Midollo Osseo. Bone Marrow Transpl. 47, 342\u2013351 (2012).","journal-title":"Bone Marrow Transpl."},{"key":"98453_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt, S. et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol. Blood Marrow Transpl. 20, 295\u2013308 (2014).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"98453_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1537-2995.1998.38498257378.x","volume":"38","author":"JA P\u00e9rez-Sim\u00f3n","year":"1998","unstructured":"P\u00e9rez-Sim\u00f3n, J. A. et al. Minimal number of circulating CD34\u2009+\u2009cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 38, 385\u2013391 (1998).","journal-title":"Transfusion"},{"key":"98453_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/bmt.2012.145","volume":"48","author":"KE Herbert","year":"2013","unstructured":"Herbert, K. E. et al. Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transpl. 48, 351\u2013356 (2013).","journal-title":"Bone Marrow Transpl."},{"key":"98453_CR29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","volume":"14","author":"I Pusic","year":"2008","unstructured":"Pusic, I. et al. Impact of mobilization and remobilization atrategies on achieving sufficient stem cell yields for autologous transplantation. Biol. Blood Marrow Transpl. 14, 1045\u20131056 (2008).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"98453_CR30","first-page":"225","volume":"90","author":"A Isidori","year":"2005","unstructured":"Isidori, A. et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 90, 225\u2013231 (2005).","journal-title":"Haematologica"},{"key":"98453_CR31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/j.1537-2995.2006.00911.x","volume":"46","author":"F Kroschinsky","year":"2006","unstructured":"Kroschinsky, F. et al. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma. Transfusion 46, 1417\u20131423 (2006).","journal-title":"Transfusion"},{"key":"98453_CR32","doi-asserted-by":"crossref","unstructured":"Neumann, T. A. Foote, M. The safety profile of filgrastim and pegfilgrastim. Twenty Years of G-CSF. 395\u2013408 (2011).","DOI":"10.1007\/978-3-0348-0218-5_21"},{"key":"98453_CR33","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/01.tp.0001068304.54904.57","volume":"108","author":"H Goto","year":"2024","unstructured":"Goto, H. et al. Efficacy and safety of single-dose pegfilgrastim for CD34\u2009+\u2009cell mobilization in healthy volunteers: a phase 2 study. Transplantation 108, 996\u20131003 (2024).","journal-title":"Transplantation"},{"key":"98453_CR34","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1007\/s00520-015-2654-4","volume":"23","author":"N Masuda","year":"2015","unstructured":"Masuda, N. et al. Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial. Support Care Cancer. 23, 2891\u20132898 (2015).","journal-title":"Support Care Cancer"},{"key":"98453_CR35","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith, T. J. et al. American Society of Clinical Oncology. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 33, 3199\u20133212 (2015).","journal-title":"J. Clin. Oncol."},{"key":"98453_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1365-2141.2006.06054.x","volume":"133","author":"C Hosing","year":"2006","unstructured":"Hosing, C. et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilization in patients with multiple myeloma. Br. J. Haematol. 133, 533\u2013537 (2006).","journal-title":"Br. J. Haematol."},{"key":"98453_CR37","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"JF DiPersio","year":"2009","unstructured":"DiPersio, J. F. et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin\u2019s lymphoma. J. Clin. Oncol. 27, 4767\u20134773 (2009).","journal-title":"J. Clin. Oncol."},{"key":"98453_CR38","doi-asserted-by":"publisher","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","volume":"113","author":"JF DiPersio","year":"2009","unstructured":"DiPersio, J. F. et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 113, 5720\u20135726 (2009).","journal-title":"Blood"},{"key":"98453_CR39","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.bbmt.2012.05.017","volume":"18","author":"AP Nademanee","year":"2012","unstructured":"Nademanee, A. P. et al. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Biol. Blood Marrow Transpl. 18, 1564\u20131572 (2012).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"98453_CR40","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s12185-017-2255-8","volume":"106","author":"M Ri","year":"2017","unstructured":"Ri, M. et al. Efficacy and safety of plerixafor for the mobilization\/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma. Int. J. Hematol. 106, 562\u2013572 (2017).","journal-title":"Int. J. Hematol."},{"key":"98453_CR41","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.bbmt.2017.04.007","volume":"23","author":"JT Stover","year":"2017","unstructured":"Stover, J. T. et al. Evaluation of hematopoietic stem cell mobilization rates with early plerixafor administration for adult stem cell transplantation. Biol. Blood Marrow Transpl. 23, 1290\u20131294 (2017).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"98453_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/bmt.2011.133","volume":"47","author":"S Abhyankar","year":"2012","unstructured":"Abhyankar, S. et al. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transpl. 47, 483\u2013487 (2012).","journal-title":"Bone Marrow Transpl."},{"key":"98453_CR43","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1111\/trf.15547","volume":"59","author":"CH Guti\u00e9rrez-Aguirre","year":"2019","unstructured":"Guti\u00e9rrez-Aguirre, C. H. et al. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study. Transfusion 59, 3721\u20133726 (2019).","journal-title":"Transfusion"},{"key":"98453_CR44","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/trf.12459","volume":"54","author":"PA Shi","year":"2014","unstructured":"Shi, P. A. et al. Plerixafor mobilization kinetics up to 18 hours. Transfusion 54, 1263\u20131268 (2014).","journal-title":"Transfusion"},{"key":"98453_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bbmt.2012.08.010","volume":"19","author":"IN Micallef","year":"2013","unstructured":"Micallef, I. N. et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol. Blood Marrow Transpl. 19, 87\u201393 (2013).","journal-title":"Biol. Blood Marrow Transpl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98453-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T13:04:35Z","timestamp":1745586275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98453"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98453-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Goto has received all support for the present manuscript from Kyowa Kirin Co., Ltd.; research funding from Kyowa Kirin Co., Ltd., Sanofi K.K., Bristol-Myers Squibb K.K., and SymBio Pharmaceuticals Ltd.; lecture fees form Bristol-Myers Squibb K.K., Novartis Pharma K.K., Eisai Co., Ltd., SymBio Pharmaceuticals Ltd., MSD K.K., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., AbbVie G.K., and Gilead Sciences, Inc.; and support for attending meetings and\/or travel from Sanofi K.K. and Chugai Pharmaceutical Co., Ltd. Dr Sawa has received lecture fees from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Astellas Pharma Inc., Nippon Shinyaku Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Bristol-Myers Squibb K.K., Asahi Kasei Pharma Corporation, Novartis Pharma K.K., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Mundipharma K.K., AbbVie G.K., CSL Behring K.K., SymBio Pharmaceuticals Ltd., Janssen Pharmaceutical K.K., AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Amgen K.K., Novo Nordisk Pharma Ltd., and Nippon Kayaku Co., Ltd.; and payment for expert testimony from Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Asahi Kasei Pharma Corporation, and AbbVie G.K. Dr Fujiwara has received lecture fees from Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Merck Ltd., Novartis Pharma K.K., and Sanofi K.K. Dr Ishida has received research funding from Janssen Pharmaceutical K.K., Bristol-Myers Squibb K.K., Sanofi K.K., Alexion Pharmaceuticals, Inc., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and PRA Health Sciences, Inc.; and lecture fees from Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., CSL Behring K.K., Pfizer Japan Inc., Bristol-Myers Squibb K.K., and Sanofi K.K. Dr Ishitsuka has received research funding from Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., AbbVie G.K., Genmab K.K., Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Bristol-Myers Squibb K.K., Mitsubishi Tanabe Pharma Corporation, Incyte Biosciences Japan G.K., Yakult Honsha Co., Ltd., and Eli Lilly Japan K.K.; consulting fees from Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Meiji Seika Pharma Co., Ltd., and Yakult Honsha Co., Ltd.; and lecture fees from Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Bristol-Myers Squibb K.K., Meiji Seika Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., AbbVie G.K., Janssen Pharmaceutical K.K., AstraZeneca K.K., Novartis Pharma K.K., Genmab K.K., Sawai Pharmaceutical Co., Ltd., Amgen K.K., Astellas Pharma Inc., Kissei Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Sanofi K.K. Dr Toyosaki has received lecture fees from Janssen Pharmaceutical K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Sanofi K.K., AbbVie G.K., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Asahi Kasei Pharma Corporation, Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd. Dr Sunami has received research funding from Ono Pharmaceutical Co., Ltd., Celgene K.K., AbbVie G.K., Sanofi K.K., Bristol-Myers Squibb K.K., GlaxoSmithKline K.K., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., MSD K.K., Novartis Pharma K.K., Pfizer Japan Inc., Kyowa Kirin Co., Ltd., Incyte Biosciences Japan G.K., Mitsubishi Tanabe Pharma Corporation, and BeiGene, Ltd.; and lecture fees from Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., and Sanofi K.K. Dr Sonoki has received research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; and lecture fees from Alexion Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sanofi K.K., Novartis Pharma K.K., and Bristol-Myers Squibb K.K. Dr Miyamoto has received research funding from Kyowa Kirin Co., Ltd. and Chugai Pharmaceutical Co., Ltd.; and lecture fees from Takeda Pharmaceutical Co., Ltd., MSD K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., and AbbVie G.K. Dr Hino has received research funding from Kyowa Kirin Co., Ltd.; consulting fees from Kyowa Kirin Co., Ltd.; and lecture fees from Kyowa Kirin Co., Ltd. Dr Maeda has received research funding from Asahi Kasei Pharma Corporation, Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Japan Blood Products Organization, Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Mallinckrodt Pharma K.K., and Regimmune Co., Ltd.; lecture fees from Kyowa Kirin Co., Ltd., Astellas Pharma Inc., Amgen K.K., AbbVie G.K., Eisai Co., Ltd., Viatris Inc., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Gilead Sciences, Inc., Konica Minolta Inc., Sanofi K.K., JCR Pharmaceutical, Celgene K.K., Bristol-Myers Squibb K.K., CSL Behring K.K., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Terumo Corporation, Chugai Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Bayer Yakuhin, Ltd., Novartis Pharma K.K., Pfizer Japan Inc., PharmaEssentia Japan K.K., Mundipharma K.K., Human Life Cord Japan Inc., Meiji Seika Pharma Co., Ltd., Janssen Pharmaceutical K.K., and Yakult Honsha Co., Ltd.; and payment for expert testimony from Meiji Seika Pharma Co., Ltd., Medical Review Co., Ltd., and Asahi Kasei Pharma Corporation. Dr Teshima has received research funding from Chugai Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Nippon Kayaku Co., Ltd., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Sumitomo Pharma Co., Ltd., Asahi Kasei Pharma Corporation, Shionogi & Co., Ltd., JCR Pharmaceutical Co., Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Luca Science Inc., Priothera SAS, and PharmaEssentia Japan K.K.; consulting fees from Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Gilead Sciences, Inc.; lecture fees from Astellas Pharma Inc., AbbVie G.K., AstraZeneca K.K., Asahi Kasei Pharma Corporation, Gilead Sciences, Inc., Nippon Shinyaku Co., Ltd., Kyowa Kirin Co., Ltd., Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb K.K., Pfizer Japan Inc., Merck&Co., Inc., Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., and Nippon Kayaku Co., Ltd.; and was a director of the Japanese Society of Hematology; president of the Japanese Society for Transplantation and Cellular Therapy; and a director of the Japan Society of Transplantation Medicine and Cell Therapy. Mr\/Ms Shimogomi, Ichihashi, and Ouchi are employees of Kyowa Kirin Co., Ltd. No other authors have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14523"}}